Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00544804 · ClinicalTrials.gov registry record · Phase 1
Lapatinib in Treating Patients With Advanced or Metastatic Breast Cancer That Overexpresses HER2
A Phase 1 study of Breast Cancer and Metastatic Cancer, sponsored by University of California, San Francisco.
- Completed
- Registry status
- Phase 1
- Development phase
- 41
- Enrollment target
- 1
- Study location
NCT00544804: Completed Phase 1 study of Breast Cancer and Metastatic Cancer, sponsored by University of California, San Francisco.
NCT00544804 is a Phase 1 study of Breast Cancer and Metastatic Cancer that has completed, run by University of California, San Francisco. The registered enrollment target is 41 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00544804, a Phase 1 study of Breast Cancer and Metastatic Cancer, has completed, sponsored by University of California, San Francisco.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 41 participants
- Enrollment target
- 1
- Study location
Study Summary
RATIONALE: Lapatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase I trial is studying the side effects and best dose of lapatinib in treating patients with advanced or metastatic breast cancer that overexpresses HER2.
Primary Outcome
Dose Escalation of 5-Day Intermittent Oral Lapatinib Therapy With Biomarker Analysis in Patients With HER2-Overexpressing Breast Cancer
Conditions Studied
Interventions
- GENETIC gene expression analysis
- OTHER diagnostic laboratory biomarker analysis
- DRUG lapatinib ditosylate
Study Locations (1)
California
- UCSF Helen Diller Family Comprehensive Cancer Center - San Francisco
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 41 participants |
| Start Date | 2007-08 |
| Est. Completion | 2013-12 |
| Phase | Phase 1 |
What the finished NCT00544804 record still lists
NCT00544804 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 41 participants, a relatively small participant target, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (99% lower).
The record links to 2 conditions, with Breast Cancer appearing as the primary indexed condition, and to 3 interventions - of which gene expression analysis is the first listed.
NCT00544804 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT00544804 about?
NCT00544804 is a clinical study titled "Lapatinib in Treating Patients With Advanced or Metastatic Breast Cancer That Overexpresses HER2". RATIONALE: Lapatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase I trial is studying the side effects and best dose of lapatinib in treating patients with advanced or metastatic breast cancer that overexpresses HER2.
What is the current status of trial NCT00544804?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 41 participants. The study started on 2007-08. Estimated completion is 2013-12.
What conditions does trial NCT00544804 study?
This clinical trial studies the following conditions: Breast Cancer, Metastatic Cancer.
What interventions are being tested in trial NCT00544804?
The interventions under investigation include: gene expression analysis (GENETIC), diagnostic laboratory biomarker analysis (OTHER), lapatinib ditosylate (DRUG).
Who is sponsoring clinical trial NCT00544804?
This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00544804 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00544804's enrollment target sits among peer trials
41 870th of 1224 higher than 350 of 1,224 other Breast Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Breast Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
VS-6766+Abema+Fulv in Met HR+/HER- BC
RECRUITING · Phase 1
-
KK-LC-1 TCR-T Cell Therapy for Gastric, Breast, Cervical, and Lung Cancer
RECRUITING · Phase 1
-
Focused Ultrasound and Gemcitabine in Breast Cancer
RECRUITING · Phase 1
-
A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies
RECRUITING · Phase 1
-
Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
A Study of MT-4561 in Patients With Various Advanced Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03449238 · 41 participants · Phase 1
Pembrolizumab And Stereotactic Radiosurgery (Srs) Of Selected Brain Metastases In Breast Cancer Patients
- NCT03900793 · 41 participants · Phase 1
Losartan + Sunitinib in Treatment of Osteosarcoma
- NCT04082520 · 41 participants · Phase 2
Lutathera for the Treatment of Inoperable, Progressive Meningioma After External Beam Radiation Therapy
- NCT04220190 · 41 participants · Phase 2
RAPA-501 Therapy for ALS
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia